Hepion Pharmaceuticals (HEPA) Competitors $0.07 -0.01 (-10.13%) As of 10/17/2025 03:45 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock HEPA vs. REVB, ARAV, VRAX, DRMA, ARTL, SRNE, LIPO, GTBP, PRFX, and PWUPShould you be buying Hepion Pharmaceuticals stock or one of its competitors? The main competitors of Hepion Pharmaceuticals include Revelation Biosciences (REVB), Aravive (ARAV), Virax Biolabs Group (VRAX), Dermata Therapeutics (DRMA), Artelo Biosciences (ARTL), Sorrento Therapeutics (SRNE), Lipella Pharmaceuticals (LIPO), GT Biopharma (GTBP), PainReform (PRFX), and PowerUp Acquisition (PWUP). These companies are all part of the "pharmaceutical products" industry. Hepion Pharmaceuticals vs. Its Competitors Revelation Biosciences Aravive Virax Biolabs Group Dermata Therapeutics Artelo Biosciences Sorrento Therapeutics Lipella Pharmaceuticals GT Biopharma PainReform PowerUp Acquisition Revelation Biosciences (NASDAQ:REVB) and Hepion Pharmaceuticals (NASDAQ:HEPA) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, valuation, analyst recommendations, institutional ownership, profitability, media sentiment, dividends and earnings. Does the media refer more to REVB or HEPA? In the previous week, Revelation Biosciences had 2 more articles in the media than Hepion Pharmaceuticals. MarketBeat recorded 3 mentions for Revelation Biosciences and 1 mentions for Hepion Pharmaceuticals. Revelation Biosciences' average media sentiment score of 0.33 beat Hepion Pharmaceuticals' score of -1.00 indicating that Revelation Biosciences is being referred to more favorably in the media. Company Overall Sentiment Revelation Biosciences Neutral Hepion Pharmaceuticals Negative Do analysts prefer REVB or HEPA? Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Revelation Biosciences 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00Hepion Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Do insiders and institutionals believe in REVB or HEPA? 12.8% of Revelation Biosciences shares are owned by institutional investors. Comparatively, 17.2% of Hepion Pharmaceuticals shares are owned by institutional investors. 0.7% of Revelation Biosciences shares are owned by insiders. Comparatively, 0.1% of Hepion Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Which has more risk & volatility, REVB or HEPA? Revelation Biosciences has a beta of -0.12, meaning that its stock price is 112% less volatile than the S&P 500. Comparatively, Hepion Pharmaceuticals has a beta of 1.52, meaning that its stock price is 52% more volatile than the S&P 500. Is REVB or HEPA more profitable? Revelation Biosciences' return on equity of -240.27% beat Hepion Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Revelation BiosciencesN/A -240.27% -148.95% Hepion Pharmaceuticals N/A -812.56%-207.31% Which has stronger earnings & valuation, REVB or HEPA? Revelation Biosciences is trading at a lower price-to-earnings ratio than Hepion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRevelation BiosciencesN/AN/A-$15.04M-$68.61-0.02Hepion PharmaceuticalsN/AN/A-$48.93M-$219.000.00 SummaryRevelation Biosciences beats Hepion Pharmaceuticals on 8 of the 11 factors compared between the two stocks. Get Hepion Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for HEPA and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding HEPA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart HEPA vs. The Competition Export to ExcelMetricHepion PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$812K$1.03B$6.09B$10.49BDividend YieldN/A4.84%5.73%4.80%P/E Ratio-0.021.3285.3027.13Price / SalesN/A147.79519.71179.96Price / CashN/A17.6337.2361.22Price / Book0.068.0712.236.52Net Income-$48.93M-$7.36M$3.33B$276.93M7 Day PerformanceN/A-1.70%1.18%1.93%1 Month PerformanceN/A27.11%6.15%2.19%1 Year PerformanceN/A-12.95%60.00%35.00% Hepion Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)HEPAHepion Pharmaceuticals0.3053 of 5 stars$0.07-10.1%N/A-99.8%$812KN/A-0.0220Negative NewsShort Interest ↑REVBRevelation Biosciences1.3136 of 5 stars$1.34flatN/A-96.8%$3.14MN/A-0.0210News CoveragePositive NewsAnalyst ForecastShort Interest ↓ARAVAraviveN/A$0.04flatN/AN/A$2.95M$6.99M0.0020High Trading VolumeVRAXVirax Biolabs Group2.6583 of 5 stars$0.67+2.4%$3.00+350.5%-61.0%$2.92M$10K0.005News CoveragePositive NewsAnalyst ForecastShort Interest ↓DRMADermata Therapeutics1.4615 of 5 stars$4.25+0.7%$10.00+135.3%-74.9%$2.89MN/A-0.268News CoverageNegative NewsShort Interest ↑ARTLArtelo Biosciences2.2563 of 5 stars$4.07-1.6%$24.00+490.4%-41.3%$2.87MN/A-0.215Short Interest ↑SRNESorrento Therapeutics0.9685 of 5 stars$0.01-9.1%N/A+62.8%$2.76M$60.32M0.00800LIPOLipella Pharmaceuticals1.1044 of 5 stars$0.58+12.7%N/A-82.6%$2.66M$536.36K-0.144Gap UpGTBPGT Biopharma2.0159 of 5 stars$0.74+0.7%$11.00+1,380.5%-67.2%$2.61MN/A-0.188Gap DownPRFXPainReform0.7965 of 5 stars$1.29+6.2%N/A-50.1%$2.59MN/A-0.014PWUPPowerUp AcquisitionN/A$0.32-4.0%N/A-97.1%$2.46MN/A0.00N/ANews CoverageGap UpHigh Trading Volume Related Companies and Tools Related Companies REVB Alternatives ARAV Alternatives VRAX Alternatives DRMA Alternatives ARTL Alternatives SRNE Alternatives LIPO Alternatives GTBP Alternatives PRFX Alternatives PWUP Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:HEPA) was last updated on 10/18/2025 by MarketBeat.com Staff From Our PartnersREVEALED: Something Big Happening Behind White House DoorsWhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredHoly ****... This could actually MAGAA new document circulating from Washington is stirring major controversy — one that some say could redefine Am...StocksToTrade | SponsoredMelt-up warning Porter Stansberry says this bull market is past the “safe zone” and racing toward an event horizon — and in hi...Porter & Company | SponsoredBuffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredNext opportunity for crypto millionsThe floodgates have opened. Bitcoin and Ethereum ETFs are seeing record-breaking inflows, the biggest since...Crypto 101 Media | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredThe End of Elon Musk…?While headlines point to collapsing sales and fading tax credits, tech analyst Jeff Brown says Tesla is on the...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Hepion Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Hepion Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free HEPA Stock Alerts